Dose Modifications in Exposure-Response Analyses of Oncology Drug Development: Brigimadlin Case Study ACoP16 (Oct 2025), Poster: M-115 Le Louedec F, Kang J, Sarr C, Neldemo I, Wiens M, Baron K, Lamar M, Pérez-Pitarch A, Schmid U, Sailer R, Bergstrand M, Busse D. ConferenceMethodologyMIDDOncologyPharmacometricsSpecial considerations Pharmetheus Affiliates Director, MIDD Consultant Félicien Le Louedec See bio Principal Director, MIDD Consultant Céline Sarr See bio Senior Director, MIDD Consultant Ida Neldemo See bio Principal Director, MIDD Scientific Lead Martin Bergstrand See bio
